HTGM
HTG Molecular Diagnostics Inc
-37.26%
$4.67 - $2.93
Feb 7th 2023 - Mar 21st 2023
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K flo... See more
Jan, 19, 2023
🚨 $HTGM on Mega Watch 🚨 Innovative life science... See more
SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Dec, 22, 2022
The power of a very low cost basis.
Dec, 2, 2022
$SAVA I’m so excited because my cost is average fo... See more
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Feb, 4, 2023
It’s not just the efficacy and safety of the produ... See more
Dec, 30, 2022
The analyst comments "TGTX stock is up >15... See more
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K float 500%+ Cost to Borrow $3M MC w/ $14M in cash Recent analyst targets of $15.00+ Excellent technical setup Also watching: $WISA $SLRX $GNUS
Jan, 19, 2023
🚨 $HTGM on Mega Watch 🚨 Innovative life science company with leading HTG platform (medicinal chemistry) tech: - 690K float - 900K outstanding - 550% Cost to Borrow (highest on market!)
Jan, 6, 2023
$HTGM I love dollar cost averaging into a long term hold.
Jan, 5, 2023
$HTGM shorts have been setup beautifully with 744 Cost to borrow 🤣🤣🤣🤣
Dec, 22, 2022
The power of a very low cost basis.
Dec, 2, 2022
$SAVA I’m so excited because my cost is average for my shares is $25.87 that’s why hahahahaha you have to be a Short and I’m semi retired hahahaha
Nov, 22, 2022
$SAVA Mike cost this morning was $31.68 This morning not too bad
Feb, 4, 2023
It’s not just the efficacy and safety of the product, it is the less cost for hospital/infusion, due to one hour infusion and the huge difference in price.
Dec, 30, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Dec, 30, 2022
Each treatment cost under $10k per treatment.
Dec, 30, 2022
Each treatment cost under $10k per treatment.
Dec, 29, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,